INS and metabolic dysfunction-associated steatotic liver disease: 2012, 2015; Schauer et al. 2012, 2017; Kashyap et al. 2013). In addition to striking improvements in body weight and insulin sensitivity, Roux‐en‐Y gastric bypass (RYGB) has also been shown to reverse non‐alcoholic fatty liver disease (NAFLD) and related steatosis, inflammation, and fibrosis (Sasaki et al. 2014; Bower et al. 2015). We have previously shown that bariatric surgery reduces insulin resistance and hepatic steatosis and inflammation from obese, non‐diabetic Sprague‐Dawley (SD) rats, and protects against endoplasmic reticulum (ER) stress and apoptosis (Mosinski et al. 2016).